MoonLake Immunotherapeutics reports results for the quarter ended September 30 - Earnings Summary

• MoonLake Immunotherapeutics reported a quarterly adjusted loss of 93 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.10. The mean expectation of thirteen analysts for the quarter was for a loss of 78 cents per share. Wall Street expected results to range from -95 cents to -66 cents per share.

• Reported revenue was zero​; analysts expected zero.

• MoonLake Immunotherapeutics's reported EPS for the quarter was a loss of 93 cents​.

• The company reported a quarterly loss of $79.55 million.

• MoonLake Immunotherapeutics shares had held steady so far this quarter and lost 11.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 14.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 2 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for MoonLake Immunotherapeutics is $30.00, about 61% above its last closing price of $11.70

This summary was machine generated from LSEG data November 4 at 01:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)